Indian govt to increase scrutiny of how drug patents are "worked" domestically
This article was originally published in SRA
Executive Summary
Large multinational firms that have been apprehensive about policy initiatives that could expand or regularise compulsory licensing in India may be able to relax for now, as the government says it does not intend to release additional guidelines for the issuance of compulsory licences for medicines1. However, with the government keeping a keen eye on the area, drug firms will have to be more proactive in disclosing how their drug patents are being worked in India.